Wiley reported third-quarter fiscal 2026 results for the period ended January 31, 2026, with revenue of USD 410 million (+1.0%), operating income of USD 63 million (+21.0%), net income of USD 30 million, and diluted EPS of USD 0.56. Adjusted EBITDA was USD 105 million (+12.0%) with an adjusted EBITDA margin of 25.7%, while adjusted EPS was USD 0.97. In segment performance, Research revenue was USD 274 million (+2.0%) and Learning revenue was USD 136 million (-1.0%). Year-to-date, net cash provided by operating activities was USD 103 million and free cash flow less product development spending was USD 56 million, with Wiley reaffirming an FY2026 free cash flow outlook of approximately USD 200 million. Wiley said it realized USD 7 million of AI revenue in Q3 and approximately USD 42 million year-to-date, launched a Clinical Outcomes Assessments partnership with IQVIA, announced a new AI and Data Services leader, and after quarter close entered a strategic partnership and recurring revenue agreement with OpenEvidence for AI clinical decision support. The company also reported USD 35 million of share repurchases in Q3 and maintained an FY2026 repurchase target of USD 100 million, while guiding to the high end of its FY2026 adjusted EBITDA margin range of 25.5% to 26.5% and adjusted EPS range of USD 3.90 to USD 4.35.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. John Wiley & Sons Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260305269505) on March 05, 2026, and is solely responsible for the information contained therein.